

Multicentric prospective study for Therapy of Erectile Dysfunction After nerve sparing radical Prostatectomy: sildenafil (50 mg daily dosing) versus intracorporeal injection of alprostadil (2.5 µg - 10 µg 3/week)

Submission date 01/08/2006	Recruitment status Stopped	☐ Prospectively registered
		☐ Protocol
Registration date 04/12/2006	Overall study status Stopped	☐ Statistical analysis plan
		☐ Results
Last Edited 18/10/2011	Condition category Urological and Genital Diseases	☐ Individual participant data
		☐ Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Ludger Franzaring

Contact details

Klinikum Bremen-Mitte gGmbH
St.-Jürgen-Str. 1
Bremen
Germany
D-28177

Additional identifiers

Protocol serial number

2006-003-TEDAP

Study information

Scientific Title

Acronym

TEDAP

Study objectives

Current hypothesis as of 25/01/2008:

The trial objective is to demonstrate a non-inferior efficacy of Sildenafil 50 mg daily dosing (Viagra-Daily-Dosing [VDD] group) compared to intracorporeal injection of Alprostadil 2.5 µg - 10 µg thrice weekly (Intra-Corporeal Injection [ICI] group) as a therapeutic option after bilateral nerve sparing prostatectomy measured by International Index of Erectile Function (IIEF-EF) domain score after 36 weeks of treatment and after 6-weeks of therapy-free interval at week 42 (follow-up one).

Previous hypothesis:

The trial objective is to demonstrate a non-inferior efficacy of sildenafil 50 mg daily dosing (Viagra-Daily-Dosing group) compared to intracorporeal injection of alprostadil 10 µg thrice weekly (Intra-Corporeal Injection group) as a therapeutic option after bilateral nerve sparing prostatectomy measured by International Index of Erectile Function (IIEF-EF) domain score after 36 weeks of treatment and after six-weeks of therapy-free-interval at week 42 (follow-up one).

Please note that as of 25/01/2008 this record was updated to show a difference in the dosage of alprostadil given to the participants. All changes relating to this update are shown in the relevant sections under the date 25/01/2008. Please also note that the title of this trial has changed from: 'Multicentric prospective study for Therapy of Erectile Dysfunction After nerve sparing radical Prostatectomy: sildenafil (50 mg daily dosing) versus intracorporeal injection of alprostadil (10 µg 3/week)' to the above-mentioned title.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the Mainz Ethics Committee (Germany) on the 25th January 2008 (ref: 837.258.06 (5356)).

Primary study design

Interventional

Study design

Prospective, randomised, open-label, multicentre phase IV study with a parallel group design.

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Erectile dysfunction

Interventions

Current interventions as of 25/01/2008:

Trial medication:

1. Viagra® (50 mg oral daily dosing)
2. Caverject Impuls® (2.5 µg - 10 µg three times weekly)

Previous interventions:

Trial medication:

1. Viagra® (VDD: Viagra-Daily-Dosing, 50 mg oral daily dosing), and
2. Caverject Impuls® (ICI: Intracorporeal injection, 10 µg three times weekly)

The study was terminated prematurely on 02/11/2010 due to an unexpected high number of drop-outs in the Caverject® group.

Intervention Type

Drug

Phase

Phase IV

Drug/device/biological/vaccine name(s)

Sildenafil and alprostadil

Primary outcome(s)

The primary outcome variable is the IIEF-EF domain score (six questions) measured at week 42, after 36 weeks of treatment and a therapy-free interval of six weeks.

Key secondary outcome(s)

Secondary endpoints are:

1. IIEF-EF domain score (six questions) after week four, 12, 24, 36, and 52.
2. IIEF domain score (15 questions) after week four, 12, 24, 36, 42 and 52.
3. Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) after week four, 12, 24, 36, 42 and 52.
4. Patient satisfaction measured by patient diary during week five, week 13, 25, 37, 42 and 51.
5. Proportion of patients achieving a normal IIEF-EF domain score (more than 25) in week four, 12, 24, 36, 42 and 52.

Completion date

01/11/2009

Reason abandoned (if study stopped)

Participant recruitment issue

Eligibility

Key inclusion criteria

1. Signed and dated informed consent indicating that the patient has been informed of all pertinent aspects of the trial before undergoing screening for the study
2. Ability of patient to understand character and individual consequences of clinical trial
3. Men older than 30 and younger than 65
4. Preoperative normal IIEF domain score more than 60 (total: 75)
5. Preoperative normal IIEF-EF domain score more than 25 (total: 30)
6. No neo-adjuvant therapy for prostate cancer before surgery

7. No use of drugs or devices for Erectile Dysfunction (ED) treatment before surgery (e.g. PDE-5-Inhibitor)
8. Patient in stable heterosexual relationship for at least six months
9. Planned surgery techniques: bilateral nerve sparing radical retropubic prostatectomy
10. No adjuvant therapy after prostatectomy (i.e. androgen deprivation, radiotherapy)
11. Documented clinical diagnosis of postoperative erectile dysfunction based on IIEF domain score less than 60
12. Documented clinical diagnosis of postoperative erectile dysfunction based on IIEF-EF domain score less than 25

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Male

Key exclusion criteria

1. Hypotension (Blood Pressure [BP] less than 90/50 mmHg)
2. Hypertension (BP more than 170/110 mmHg)
3. Patients with significant cardiovascular diseases in the last six months, including cardiac failure, myocardial infarction, unstable angina, stroke, symptomatic or clinically significant arrhythmias
4. Patients with blood coagulation disorder
5. Patients who are advised against sexual activity for medical reasons (e.g. patients with severe cardiovascular disorders)
6. Patients who have conditions that might predispose them to priapism, such as sickle cell anaemia or trait, multiple myeloma, or leukaemia
7. Patients with severe liver insufficiency (e.g. cirrhosis, CHILD C)
8. Patients with severe kidney insufficiency (Creatinin-Clearance less than 30 ml/min)
9. Patients with hereditary degenerative retinal disorders such as Retinitis pigmentosa
10. Patients suffering from loss of vision on one eye due to Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
11. Patients with anatomical deformation of penis, such as angulation, cavernosal fibrosis or Peyronie's disease
12. Known hypersensitivity to Sildenafil, Alprostadil or any compound of the trial medication
13. Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
14. Any of the investigational drugs taken four weeks prior to screening
15. Patients who are currently prescribed, taking and/or likely to be treated with nitrates or nitric oxide donors in any form on either a regular or intermittent basis
16. Patients being treated with alpha blockers for therapy of arterial hypertension
17. Patients who are receiving concomitant treatment with CYP3A4 inhibitor (e.g. ritonavir)
18. Alcohol or drug abuse
19. Participation in any other trial

Date of first enrolment

01/11/2006

Date of final enrolment

01/11/2009

Locations

Countries of recruitment

Germany

Study participating centre

Klinikum Bremen-Mitte gGmbH

Bremen

Germany

D-28177

Sponsor information

Organisation

Johannes Gutenberg Universität Mainz (Germany)

ROR

<https://ror.org/023b0x485>

Funder(s)

Funder type

Industry

Funder Name

Pfizer Pharma GmbH (Germany)

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Not provided at time of registration

